PDCD1 and melanoma: In anti-PD-1-treated melanoma patients, MHC-II positivity in addition to ubiquitous MHC-I expression has been associated with CD4+ and CD8+ T cell infiltrates and has been predictive for the response to PD-1 blockade and overall survival [39].